(E)-4-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-9H-purin-8-yl)-cinnamic acid | 106465-41-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-4-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-9H-purin-8-yl)-cinnamic acid
• 英文别名: (E)-4-(1,2,3,6-Tetrahydro-1,3-dimethyl-2,6-dioxo-9H-purin-8-yl)cinnamic acid；(E)-3-[4-(1,3-dimethyl-2,6-dioxo-7H-purin-8-yl)phenyl]prop-2-enoic acid
• CAS: 106465-41-2
• 化学式: C₁₆H₁₄N₄O₄
• 分子量: 326.312
• InChiKey: BLTGSBVSJOCCTK-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(4-甲酰基苯基)丙-2-烯酸 、 5,6-Diamino-1,3-dimethyluracil hydrate 以 硝基苯 为溶剂， 生成 (E)-4-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-9H-purin-8-yl)-cinnamic acid
  参考文献：
  名称：

  Xanthine derivatives

  摘要：

  本发明涉及某些新颖的8-苯基黄嘌呤，其在苯基团的3或4位置被烯基、烯基氧、炔基或炔基氧取代，这些化合物带有末端酸性基团，并且适用于人类和兽医治疗，特别是用于与腺苷效应相关的细胞表面效应的疾病。

  公开号：

  US04879296A1

文献信息

• Method for treating viral infections
  申请人：Burroughs Wellcome Co.

  公开号：US05015647A1

  公开（公告）日：1991-05-14

  The present invention relates to certain novel 8-phenylxanthines substituted in the 3 or 4 position of the phenyl group by an alkenylene, alkenyleneoxy, alkynylene or alkynyleneoxy bearing a terminal acidic grouping, and to their use in human and veterinary therapy, particularly for conditions associated with the cell surface effects of adenosine and in antiviral, especially antiretroviral, chemotherapy.

  本发明涉及某些新颖的8-苯基黄嘌呤，其在苯基团的3或4位被烯基烷基，烯基烷氧基，炔基烷基或炔基烷氧基取代，并且其在人类和兽医治疗中的应用，特别是用于与腺苷效应相关的细胞表面效应和抗病毒，尤其是抗逆转录病毒化疗。
• Methods for treating viral infection
  申请人：Burroughs Wellcome Co.

  公开号：US05017577A1

  公开（公告）日：1991-05-21

  The present invention relates to certain novel 8-phenylxanthines substituted in the 3 or 4 position of the phenyl group by an alkenylene, alkenyleneoxy, alkynylene or alkynyleneoxy bearing a terminal acidic grouping, and to their use in human and veterinary therapy, particularly for conditions associated with the cell surface effects of adenosine and in antiviral, especially antiretroviral, chemotherapy.

  本发明涉及某些新型的8-苯基黄嘌呤，其在苯基上的3或4位被烯基、烯基氧基、炔基或炔基氧基取代，带有末端酸性基团，并且它们在人类和兽医治疗中的应用，特别是用于与腺苷效应相关的细胞表面效应以及抗病毒，尤其是抗逆转录病毒化疗方面。
• Use of adenosine antagonists in the treatment of bradyarrhythmias and
  申请人：The University of Virginia

  公开号：US04980379A1

  公开（公告）日：1990-12-25

  A method to enhance the efficacy of cardioversion, defibrillation, cardiac pacing, and cardiopulmonary resuscitation and to treat post-resuscitation asystole, bradyarrhythmias, electromechanical dissociation, and hemodynamic collapse by administering to a human or animal an effective amount of an adenosine antagonist that competitively inhibits adenosine or that reduces the level of adenosine present in myocardial and vascular tissues and associated fluids.

  一种增强心脏复律、除颤、心脏起搏和心肺复苏疗效，并治疗复苏后心跳停止、心动过缓、电机分离和血流动力学崩溃的方法是向人类或动物施加有效剂量的腺苷拮抗剂，该腺苷拮抗剂具有竞争性地抑制腺苷或降低心肌和血管组织及相关液体中腺苷水平的作用。
• Purine Derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04981857A1

  公开（公告）日：1991-01-01

  The present invention relates to certain novel 8-phenylxanthines substituted in the 3 or 4 position of the phenyl group by an alkenylene, alkenyleneoxy, alkynylene or alkynyleneoxy bearing a terminal acidic grouping, and to their use in human and veterinary therapy, particularly for conditions associated with the cell surface effects of adenosine.

  本发明涉及某些新型8-苯基黄嘌呤，其在苯基团的3或4位置被烯基，烯基氧，炔基或炔基氧取代，带有末端酸性基团，并且它们在人类和兽医疗法中的使用，特别是用于与腺苷细胞表面效应相关的病症。
• 8-Phenyl xanthines
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0203721A2

  公开（公告）日：1986-12-03

  The present invention relates to certain novel 8-phenylxanthines substituted in the 3 or 4 position of the phenyl group by an alkenylene, alkenyleneoxy, alkynylene or alkynyleneoxy bearing a terminal acidic grouping, and to their use in human and veterinary therapy, particularly for conditions associated with the cell surface effects of adenosine.

  本发明涉及某些新型 8-苯基黄嘌呤，其苯基的 3 或 4 位被带有末端酸性基团的烯基、烯氧基、炔基或炔氧基取代，并涉及它们在人类和兽医治疗中的用途，特别是用于治疗与腺苷的细胞表面效应有关的疾病。